|
Patent landscape, scope, and claims: |
Patent 9,994,575 (US9994575) scope and claims analysis: What compound, salt, composition, and therapeutic method coverage does the Formula II estate provide?
US 9,994,575 is a US patent with a broad Markush-style claim set centered on “a compound of Formula II” and dependent fallbacks narrowing to specific sub-choices of the variables. The independent claim scope is dominated by three structural variable blocks: (i) a Ring A and Z aromatic/heteroaromatic substituent framework; (ii) a linker L selected from a dense list of bond/alkylene/heteroalkylene/carbonyl/heteroatom-containing linkers; and (iii) substituent patterns (RC, Ra/Rb, and R2/R″) that are individually allowed to vary widely, including halogenation (notably fluoro), heteroatom-rich fragments, and multiple ring systems. The downstream dependent claims add product-by-formulation and therapeutic method coverage for mastocytosis, gastrointestinal stromal tumor (GIST), and acute myeloid leukemia (AML), with additional subclassification for mastocytosis subtypes.
What patents protect US 9,994,575 compound-of-Formula II coverage and where does the estate sit inside the broader IP stack?
US 9,994,575 itself is the core chemical and use patent. The text you provided includes compound, salt, composition, and method-of-treatment claim types, so this patent typically functions as both a primary compound patent and a scaffold for secondary infringement theories (therapeutic use) against branded product and generics/biosimilars where applicable.
Because the question is specifically about US 9,994,575 and you have provided only the claim text (not the patent family, assignee, priority, or citation set), this analysis treats US 9,994,575 as the only identified document and does not infer other patents, continuation filings, or family members.
Claim types present in US 9,994,575
- Product (chemical compound) claim: Claim 1, compound of Formula II with Ring A/Z/L and multiple substituent variables.
- Product (pharmaceutically acceptable salt): Claim 1 and dependencies cover salts of the Formula II compounds.
- Additional compound narrowing: Claims 2, 3, 4–11, 18–20.
- Formulation claim: Claim 12 covers a pharmaceutical composition with carrier + compound/salt.
- Method-of-use claims (therapeutic):
- Claim 13: mastocytosis
- Claim 14: GIST
- Claim 15: AML
- Claims 16–17: mastocytosis subtype subdivisions
- Specific variable exemplars inside the Markush: Claims 11 and 19–20 specify RA = fluoro and q = 1, and force Z or L variants.
How broad are the claims in US 9,994,575 and which variable blocks drive the claim breadth?
Executive read-through (how infringement can occur)
At the claim-1 level, infringement does not require a single fixed molecule. It requires a compound that satisfies all selected options within Formula II. The breadth comes from:
- allowing multiple classes of ring systems for Ring A and Z,
- allowing multiple linker types L (including heteroatom linkers and sulfone/sulfinamide style fragments),
- allowing wide substituent permutations at multiple attachment points (RC and Ra/Rb, plus R2 and R″),
- and allowing multiple values for m, p, q (each 0–4).
Key “breadth levers”
- Ring A options (Claim 1): monocyclic/bicyclic aryl, monocyclic/bicyclic heteroaryl, cycloalkyl, or heterocyclyl.
- Z options (Claim 1): C1–C6 alkyl; cycloalkyl; aryl/aralkyl; heteroaryl/heterocyclyl; heterocyclylalkyl. Each of those fragments can be substituted with 0–5 occurrences of RC.
- L options (Claim 1): very long Markush list spanning:
- direct bond,
- substituted “(C(R2)(R2))m” motifs,
- C2–C6 alkynylene, alkenylene,
- haloalkylene, heteroalkylene, hydroxyalkylene,
- carbonyl and oxygen/sulfur/nitrogen-containing linkers, including sulfone patterns like “S(O)2—” and sulfonamide-like “N(R2)—S(O)2—(… )”.
- Substituent universe for RC, R2, Ra/Rb, Ra and Rb: includes halogens (including haloalkyl and haloalkoxy), multiple heteroatoms, cyano, carbonyl esters/amides/sulfones, and ring-forming allowances (“2 RC together with the carbon atom(s) … form a cycloalkyl or heterocyclyl ring”).
What is the exact scope of Claim 1 (Formula II) in US 9,994,575?
Claim 1 defines:
“A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein …”
Because Formula II itself is not reproduced in your prompt (the claim text describes variable definitions but not the full drawn skeleton), scope must be described in terms of variable constraints stated in the claim.
1) Ring A (topological head group)
- Ring A is selected from:
- monocyclic or bicyclic aryl
- monocyclic or bicyclic heteroaryl
- cycloalkyl
- heterocyclyl
2) Z (ring-substituted position)
- Z is selected from:
- C1–C6 alkyl
- cycloalkyl
- monocyclic/bicyclic aryl
- monocyclic/bicyclic aralkyl
- monocyclic/bicyclic heteroaryl
- monocyclic/bicyclic heterocyclyl
- monocyclic/bicyclic heterocyclylalkyl
- Each of the enumerated fragments (for those categories) is independently substituted with 0–5 occurrences of RC.
3) Linker L (connects core elements)
L is selected from the following set (verbatim concept list from the claim):
- bond
- —(C(R2)(R2))m—
- —(C2–C6 alkynylene)—
- —(C2–C6 alkenylene)—
- —(C1–C6 haloalkylene)—
- —(C1–C6 heteroalkylene)—
- —(C1–C6 hydroxyalkylene)—
- —C(O)—
- —O—
- —S—
- —S(O)—
- —S(O)2—
- —N(R2)—
- plus multiple carbonyl/ether/amine substituted variants, including:
- —O—(C1–C6 alkylene)—
- (C1–C6 alkylene)—O—
- N(R2)—C(O)—
- C(O)—N(R2)—
- (C1–C6 alkylene)—N(R2)—
- N(R2)—(C1–C6 alkylene)—
- N(R2)—C(O)—(C1–C6 alkylene)—
- C(O)—N(R2)—(C1–C6 alkylene)—
- N(R2)—S(O)2—
- S(O)2—N(R2)—
- N(R2)—S(O)2—(C1–C6 alkylene)—
- S(O)2—N(R2)—(C1–C6 alkylene)—
4) Substituent definitions on each RC-bearing region
- Each RA and RB is independently selected from:
- C1–C6 alkyl
- C3–C6 cycloalkyl
- C3–C6 heterocyclyl
- halo
- C1–C6 haloalkyl
- C1–C6 hydroxyalkyl
- C1–C6 heteroalkyl
- monocyclic/bicyclic aralkyl
- —N(R2)(R2)
- cyano
- —OR2
- Each RC is independently selected from an expanded list including:
- C1–C6 alkyl
- C2–C6 alkynyl
- halo
- C1–C6 heteroalkyl
- C1–C6 haloalkyl
- C1–C6 haloalkoxy
- C1–C6 hydroxyalkyl
- cycloalkyl
- aryl, aryloxy, aralkyl
- heterocyclylalkyl
- nitro
- cyano
- carbonyl substituents: —C(O)R2, —OC(O)R2, —C(O)OR2
- thio and sulfone variants: —SR2, —S(O)2R2, —S(O)2—N(R2)(R2)
- sulfone linked: —(C1–C6 alkylene)—S(O)2—N(R2)(R2)
- —N(R2)(R2), and multiple amide/sulfonamide-like motifs.
Cyclization allowance:
- “or 2 RC together with the carbon atom(s) to which they are attached form a cycloalkyl or heterocyclyl ring substituted with 0–5 occurrences of Ra.”
5) R2 (core substituent at multiple positions)
- Each R2 independently selected from:
- hydrogen, hydroxyl, halo, thiol
- C1–C6 thioalkyl
- —NR″R″
- C1–C6 alkyl, alkoxy
- haloalkyl, hydroxyalkyl
- cycloalkyl, cycloalkylalkyl
- heterocyclyl, heterocyclylalkyl
- Substitution limit: “wherein each of C1–C6 alkyl, cycloalkyl, and heterocyclyl is independently substituted with 0–5 occurrences of Rb, or 2 R2 together…” forms ring.
6) Ra and Rb
- Each Ra and Rb independently selected from:
- hydrogen, halo, cyano, hydroxyl
- C1–C6 alkoxyl
- —C(O)R′, C(O)OR′
- C1–C6 alkyl, haloalkyl, heteroalkyl, hydroxyalkyl
- —NR′R′
- cycloalkyl (cycloalkyl substituted with 0–5 occurrences of R′)
- Each R′ is hydrogen, hydroxyl, or C1–C6 alkyl.
7) R″
- Each R″ is hydrogen, C1–C6 alkyl, —C(O)—C1–C6 alkyl, —C(O)—NR′R′, or —C(S)—NR′R′.
8) Ring substitution count variables
- m, p, q each independently 0, 1, 2, 3, or 4.
Which dependent claims narrow the Formula II scope most in US 9,994,575?
Claim 2, 3, 4–11, and 18–20 function as narrowing constraints (typically “select one subset from within claim 1”).
Claim 2: Formula III embedding
- Claim 2 states the compound is a compound of Formula III (where Formula III is not provided in the prompt). In practice, this is usually narrower than Claim 1 and ties to a specific structural instantiation while still covering the salt form.
Claim 3: specific linker L subgroup
- “wherein L is —(C(R2)(R2))m—.”
Claim 4: Ring A narrowed
- “wherein A is monocyclic or bicyclic aryl.”
Claims 5–7 and 9–10: Z narrowed to specific hetero/aryl classes
- Claim 5: Z is monocyclic or bicyclic aryl.
- Claim 6: Z is monocyclic or bicyclic heteroaryl.
- Claim 7: Z is monocyclic heteroaryl.
- Claim 8: Z is selected from pyrazolyl, isoxazolyl, thiophenyl, thiazolyl, and pyridyl.
- Claim 9: Z is phenyl.
- Claim 10: Z is monocyclic or bicyclic heterocyclyl.
Claim 11 and 20: a specific substituent profile
- Claim 11: “RA is fluoro and q is 1.”
- Claim 20 repeats: “wherein RA is fluoro and q is 1.”
Claim 18–19: reasserting specific L and Z subsets for compounds of Formula II
- Claim 18: “wherein L is —(C(R2)(R2))m—.”
- Claim 19: “wherein Z is monocyclic or bicyclic heteroaryl.”
What formulation (composition) protection exists in US 9,994,575?
Claim 12:
- “A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.”
This is a standard composition claim that can support infringement theories for a branded product and may also reach generic products if the generic’s formulation contains the claimed active compound (or a salt form that meets the claim limitations).
What method-of-treatment indications are claimed in US 9,994,575?
US 9,994,575 contains use claims for three oncology/hematology therapeutic targets.
Claim 13: Mastocytosis
- Administer therapeutically effective amount of the claimed compound/salt to treat mastocytosis.
Claim 16: mastocytosis subtype (CM vs SM)
- “mastocytosis is selected from cutaneous mastocytosis (CM) and systemic mastocytosis (SM).”
Claim 17: systemic mastocytosis subdivisions
- Systemic mastocytosis selected from:
- indolent systemic mastocytosis (ISM)
- smoldering systemic mastocytosis (SSM)
- aggressive systemic mastocytosis (ASM)
- SM with associated hematologic non-mast cell lineage disease (SM-AHNMD)
- mast cell leukemia (MCL)
Claim 14: Gastrointestinal stromal tumor (GIST)
- Treat GIST by administering the compound/salt.
Claim 15: Acute myeloid leukemia (AML)
- Treat AML by administering the compound/salt.
Implication for enforcement: these claims allow infringement theories focused on prescribing and administering the claimed compound for these specific diseases, even if the formulation itself is not uniquely defined beyond the presence of the compound and carrier.
How strong is the patent estate coverage for likely generic design-arounds under the claim structure in US 9,994,575?
Chemical scope and typical design-around pressure points
In Markush chemical claims, the main design-around routes typically include:
- Avoiding the exact linker class L used in the asserted claim subset (e.g., if only claim-3-style L is asserted).
- Changing the selected Z category (e.g., if a specific Z subgroup like pyrazolyl/isoxazolyl/thiophene/thiazole/pyridyl or phenyl is targeted via dependent claims).
- Changing key substituent constraints such as RA being fluoro with q = 1 (dependent claim 11/20).
- Using alternative salts does not necessarily help because salts are explicitly covered, unless the alternative is not “pharmaceutically acceptable” under the claim framing or avoids the corresponding parent compound.
Practical risk posture
- Against claim 1: high risk of coverage for many structural variants because claim 1 is a broad Markush scaffold that allows many ring and substituent options.
- Against dependent claim assertions: risk narrows to the particular subset. If a defendant can avoid the required L subgroup or Z subgroup or RA/q constraints, they may avoid those dependent claim theories, but claim 1 remains a wide backstop unless the asserted claim is limited to the narrower dependent language.
How does the claim scope map to competitive landscape risks (branded product vs generic entry scenarios)?
With the claim set including compound/salt, composition, and multiple therapeutic method claims, the patent can be asserted across:
- ANDAs: if an oral small molecule exists and the generic includes a compound meeting the claim limitations, the compound claim and composition claim are primary targets; method-of-use can support additional theories depending on jurisdictional enforcement standards.
- Carve-out dynamics: any generic entry that uses a non-claimed active (different scaffold not meeting Formula II) can avoid chemical/product and composition claims, but may still face method-of-use theories if the active is not the generic’s marketed drug.
This patent’s breadth suggests it is built to capture structural variants rather than a single embodiment.
What Orange Book status or FDA exclusivity impact would matter for US 9,994,575?
No FDA product, application number, listed patents, or Orange Book entry for US 9,994,575 is provided in your prompt. Without those identifiers, no definitive Orange Book alignment can be established here.
Key takeaways
- Claim 1 (Formula II) is the breadth anchor: it covers a wide Markush set spanning multiple ring classes (Ring A, Z), an extensive linker list (L), and broad substituent options (RC, Ra/Rb, R2/R″) with m/p/q from 0 to 4.
- Dependent claims provide multiple “narrowing switches”: specific linker form (—(C(R2)(R2))m—), specific Z classes (aryl/heteroaryl/heterocyclyl; specific heteroaryl examples), and a concrete substituent profile (RA = fluoro; q = 1).
- Non-chemical coverage exists: Claim 12 adds a pharmaceutical composition claim; Claims 13–17 add method-of-treatment coverage for mastocytosis (with CM/SM and SM subtypes), GIST, and AML.
- Generic design-around risk is structured around variable avoidance: avoiding the exact chosen L subgroup, Z subgroup, or RA/q constraint can defeat dependent-claim assertions, but claim 1 remains a wide backstop unless the active compound is outside the Formula II scaffold.
FAQs
1) Does US 9,994,575 claim only specific compounds or an entire Markush class?
It claims “a compound of Formula II,” using Markush-style variable selections that permit many structural permutations, plus pharmaceutically acceptable salts.
2) Are salts and formulations covered separately from the compound?
Yes. Claim 1 covers pharmaceutically acceptable salts, and Claim 12 covers a pharmaceutical composition containing a claimed compound/salt plus a carrier.
3) Which diseases are covered by the method claims?
Mastocytosis (including CM and SM subtypes), gastrointestinal stromal tumor (GIST), and acute myeloid leukemia (AML).
4) What specific dependent claim constraints could be used to narrow coverage?
Examples include L limited to —(C(R2)(R2))m— and Z limited to selected aryl/heteroaryl classes, plus RA = fluoro with q = 1.
5) What are the main chemical design-around levers under the claim language?
Avoiding the claimed Formula II variable combinations for Ring A/Z selection, the selected linker L category, and any dependent-claim-specific substituent constraints (such as RA = fluoro and q = 1).
References (APA)
- United States Patent No. 9,994,575. (n.d.). Claims provided in user prompt.
More… ↓
⤷ Start Trial
|
